Amgen Stock Treads Near 52-Week High on Q2 Beat
Amgen's stock price has reached near its 52-week high, trading at around $439.23 USD on September 2, 2026, as the biotechnology group continues to impress investors with its performance.
The company's Q2 2026 earnings beat expectations, with earnings per share coming in at $6.29 USD, surpassing analysts' projections of $5.62 USD by $0.67 USD. This significant outperformance was also reflected in the revenue growth, which reached a staggering 9.5% year-over-year.
Amgen's ability to convert sales into bottom-line earnings is evident from its profit margin of 22.95%, with diluted EPS standing at $16.09 USD over the trailing twelve months. The company's guidance for fiscal year 2026 also suggests that it will continue to perform well, with a forward earnings multiple in the low 20s.
The cholesterol-lowering drug Repatha has emerged as one of the key growth drivers within Amgen's portfolio, achieving sales growth of 37% year-over-year in the recent reporting period. This highlights the company's diversified revenue streams and its ability to drive growth across various product lines.